Expert Interview
A Second Opinion: Discussing the standard of care and/or the potential of Vabysmo (faricimab-svoa) and the recent label expansion approved by the FDA to include treatment of RVO
Ticker(s): RHHBY, REGNInstitution: Private practice
- Pediatric & Adult Retina Specialist; treats 15-20 patients a week with Geographic Atrophy.
- Clinical and research interests include retinopathy of prematurity, Coats' disease, familial exudative vitreoretinopathy, persistent fetal vasculature, macular degeneration, diabetic retinopathy, macular holes, retinal detachments, proliferative vitreoretinopathy, and ocular trauma.
- Has published over 30 peer reviewed manuscripts and book chapters in internationally esteemed journals, including PNAS, Nanomedicine, Ophthalmology, Retina, and IOVS.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
